Brian Robb Douglass
CIK: 0002104618
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (50.0%)
Compensation grants
Other (G, F, J, C, D, …)2 (50.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
RGEN
REPLIGEN CORP
Officer
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Oct 6, 2026RGEN
REPLIGEN CORP
Award(A)Direct700 shares- - May 7, 2026RGEN
REPLIGEN CORP
Tax Payment(F)Direct334 shares at avg. $126.43$42K - Mar 2, 2026RGEN
REPLIGEN CORP
Tax Payment(F)Direct221 shares at avg. $124.97$28K - Dec 31, 2025RGEN
REPLIGEN CORP
Award(A)Direct2.3K shares-
1-4 of 4 transactions
About Douglass Brian Robb
Douglass Brian Robb (SEC CIK 0002104618) files insider reports with the SEC as CHIEF PRODUCT OFFICER of REPLIGEN CORP (RGEN).
Signal8 holds 5 ownership filings by Douglass Brian Robb (1 Form 3, 4 Form 4), filed between Jan 12, 2026 and Oct 8, 2026. Those filings report 4 transactions, from Dec 31, 2025 to Oct 6, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Douglass Brian Robb's filings is in WALTHAM, MA.
Recent filings by Douglass Brian Robb
Other insiders filing for REPLIGEN CORP (RGEN)
- Loeillot Olivier, Chief Executive Officer
- Garland Jason K, CFO
- Hughes Violetta, CHIEF ACCOUNTING OFFICER
- Madaus Martin D, Director
- Konstantinov Konstantin, Director
- Mhatre Rohin, Director